TABLE 1—
Hepatitis C Virus (HVC) Infection and Treatment Characteristics of Analysis Sample (N = 80), by Percentage of Sustained Virological Response and χ2 Test
| Sustained Virological Response, % (n) | χ2 | |
| HCV genotype (n) | ||
| 1 (38) | 47.4 (18) | 13.6, P < .01 |
| 2 (12) | 100.0 (12) | |
| 3 (30) | 76.7 (23) | |
| Age, y (n) | ||
| 20–34 (28) | 75.0 (21) | 2.2, P = .331 |
| 35–49 (42) | 64.3 (27) | |
| 50–64 (10) | 50.0 (5) | |
| Methadone maintenance treatment (n) | ||
| Yes (26) | 80.8 (21) | 3.6, P = .057 |
| No (54) | 59.3 (32) | |
| HCV risk factors, self-reported (n) | ||
| Injection drug use (alone or in combination with other risks) (44) | 77.3 (34) | 7.2, P = .027 |
| Noninjection drug use risks (21) | 61.9 (13) | |
| Unknown (15) | 40.0 (6) | |
| Treatment course (n) | ||
| Completed (63) | 79.4 (50) | 23.1, P < .01 |
| Not completed or stopped early (17) | 17.6 (3) | |
| Overall | 66.3 (53) | |
| (95% CI = 56.1%, 77.6%) | ||
Note. CI = confidence interval.